{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T03:31:30Z","timestamp":1793676690878,"version":"4.5.1"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s13555-025-01517-9","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T10:18:55Z","timestamp":1754993935000},"page":"2749-2764","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Evaluating Current and Emergent JAK Inhibitors for Alopecia Areata: A Narrative Review"],"prefix":"10.1007","volume":"15","author":[{"given":"Katherine","family":"Sanchez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Englander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lana","family":"Salloum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Gregoire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Biba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherry","family":"Ershadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6084-5617","authenticated-orcid":false,"given":"Arash","family":"Mostaghimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"1517_CR1","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s12016-021-08883-0","volume":"61","author":"C Zhou","year":"2021","unstructured":"Zhou C, Li X, Wang C, Zhang J. Alopecia areata: an update on etiopathogenesis, diagnosis, and management. Clin Rev Allergy Immunol. 2021;61:403\u201323.","journal-title":"Clin Rev Allergy Immunol"},{"key":"1517_CR2","first-page":"409","volume":"13","author":"M Lundin","year":"2014","unstructured":"Lundin M, Chawa S, Sachdev A, Bhanusali D, Seiffert-Sinha K, Sinha AA. Gender differences in alopecia areata. J Drugs Dermatol JDD. 2014;13:409\u201313.","journal-title":"J Drugs Dermatol JDD"},{"key":"1517_CR3","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.jaad.2019.08.032","volume":"82","author":"HH Lee","year":"2020","unstructured":"Lee HH, Gwillim E, Patel KR, Hua T, Rastogi S, Ibler E, et al. Epidemiology of alopecia areata, ophiasis, totalis, and universalis: A systematic review and meta-analysis. J Am Acad Dermatol. 2020;82:675\u201382.","journal-title":"J Am Acad Dermatol"},{"key":"1517_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jdermsci.2016.10.004","volume":"86","author":"T Dainichi","year":"2017","unstructured":"Dainichi T, Kabashima K. Alopecia areata: what\u2019s new in epidemiology, pathogenesis, diagnosis, and therapeutic options? J Dermatol Sci. 2017;86:3\u201312.","journal-title":"J Dermatol Sci"},{"key":"1517_CR5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.crimmu.2021.02.001","volume":"2","author":"J(T Olayinka","year":"2021","unstructured":"Olayinka J(T, Richmond JM. Immunopathogenesis of alopecia areata. Curr Res Immunol. 2021;2:7\u201311.","journal-title":"Curr Res Immunol"},{"key":"1517_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4103\/ijt.ijt_28_21","volume":"15","author":"K Malhotra","year":"2023","unstructured":"Malhotra K, Madke B. An updated review on current treatment of Alopecia areata and newer therapeutic options. Int J Trichology. 2023;15:3\u201312.","journal-title":"Int J Trichology"},{"key":"1517_CR7","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.1038\/jid.2014.260","volume":"134","author":"BG Craiglow","year":"2014","unstructured":"Craiglow BG, King BA. Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis. J Invest Dermatol. 2014;134:2988\u201390.","journal-title":"J Invest Dermatol"},{"key":"1517_CR8","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nature09114","volume":"466","author":"L Petukhova","year":"2010","unstructured":"Petukhova L, Duvic M, Hordinsky M, Norris D, Price V, Shimomura Y, et al. Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. Nature. 2010;466:113\u20137.","journal-title":"Nature"},{"key":"1517_CR9","doi-asserted-by":"publisher","first-page":"100","DOI":"10.31138\/mjr.31.1.100","volume":"31","author":"CM Lin","year":"2020","unstructured":"Lin CM, Cooles FA, Isaacs JD. Basic mechanisms of JAK inhibition. Mediterr J Rheumatol. 2020;31:100.","journal-title":"Mediterr J Rheumatol"},{"key":"1517_CR10","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/nm.3645","volume":"20","author":"L Xing","year":"2014","unstructured":"Xing L, Dai Z, Jabbari A, Cerise JE, Higgins CA, Gong W, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med. 2014;20:1043\u20139.","journal-title":"Nat Med"},{"issue":"15","key":"1517_CR11","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.89790","volume":"1","author":"J Mackay-Wiggan","year":"2016","unstructured":"Mackay-Wiggan J, Jabbari A, Nguyen N, Cerise JE, Clark C, Ulerio G, et al. Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata. JCI Insight. 2016;1(15): e89790.","journal-title":"JCI Insight"},{"key":"1517_CR12","first-page":"1","volume":"28","author":"J Donovan","year":"2023","unstructured":"Donovan J. The evolving story of JAK inhibitors for treating alopecia areata: a review of current progress and future directions. Skin Ther Lett. 2023;28:1\u20137.","journal-title":"Skin Ther Lett"},{"key":"1517_CR13","unstructured":"Approved treatments for alopecia areata [Internet]. Natl. Alopecia Areata Found. [Cited 2024 Nov 17]. Available from: https:\/\/www.naaf.org\/approved-treatment-drug-page\/"},{"key":"1517_CR14","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1080\/1744666X.2023.2249237","volume":"19","author":"K Tokareva","year":"2023","unstructured":"Tokareva K, Reid P, Yang V, Liew D, Peterson AC, Baraff A, et al. JAK inhibitors and black box warnings: what is the future for JAK inhibitors? Expert Rev Clin Immunol. 2023;19:1385\u201397.","journal-title":"Expert Rev Clin Immunol"},{"key":"1517_CR15","unstructured":"Ahmad A, Zaheer M, Balis F. Baricitinib [Internet]. StatPearls; (2024). Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK572064\/"},{"key":"1517_CR16","unstructured":"Lepe K, Syed H, Zito P. Alopecia Areata [Internet]. StatPearls; Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK537000\/"},{"key":"1517_CR17","unstructured":"Olumiant\u00ae (baricitinib) prescribing information [Internet]. Eli Lilly and Company; (2024). Available from: https:\/\/uspl.lilly.com\/olumiant\/olumiant.html#pi"},{"key":"1517_CR18","unstructured":"Olumiant: Getting Patients Started \u2013 Dosing and Administration. [Internet]. Eli Lily and Company; Available from: https:\/\/chatgpt.com\/c\/67df3e5b-5890-8013-94a5-11e3017349da"},{"issue":"3","key":"1517_CR19","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s40257-023-00764-w","volume":"24","author":"O Kwon","year":"2023","unstructured":"Kwon O, Senna MM, Sinclair R, Ito T, Dutronc Y, Lin C-Y, et al. Efficacy and safety of baricitinib in patients with severe alopecia areata over 52 weeks of continuous therapy in two phase III trials (BRAVE-AA1 and BRAVE-AA2). Am J Clin Dermatol. 2023;24(3):443\u201351.","journal-title":"Am J Clin Dermatol"},{"key":"1517_CR20","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","volume":"386","author":"B King","year":"2022","unstructured":"King B, Ohyama M, Kwon O, Zlotogorski A, Ko J, Mesinkovska NA, et al. Two phase 3 trials of baricitinib for alopecia areata. N Engl J Med. 2022;386:1687\u201399.","journal-title":"N Engl J Med"},{"key":"1517_CR21","doi-asserted-by":"crossref","unstructured":"There are early, gradual and late responders for scalp hair regrowth in patients with alopecia areata treated with baricitinib. Br J Dermatol. (2023)189: e104\u2013e104","DOI":"10.1093\/bjd\/ljad415"},{"key":"1517_CR22","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1001\/jamadermatol.2023.2581","volume":"159","author":"JM Ko","year":"2023","unstructured":"Ko JM, Mayo TT, Bergfeld WF, Dutronc Y, Yu G, Ball SG, et al. Clinical outcomes for uptitration of baricitinib therapy in patients with severe alopecia areata: a pooled analysis of the BRAVE-AA1 and BRAVE-AA2 trials. JAMA Dermatol. 2023;159:970.","journal-title":"JAMA Dermatol"},{"key":"1517_CR23","doi-asserted-by":"publisher","DOI":"10.25251\/skin.7.supp.296","volume":"7","author":"B King","year":"2023","unstructured":"King B, Ohyama M, Senna M, Shapiro J, Dutronc Y, Kolodsick J, et al. Outcomes of down-titration in patients with severe scalp alopecia areata treated with baricitinib: an update through week 152 from BRAVE-AA2. SKIN J Cutan Med. 2023;7: s296.","journal-title":"SKIN J Cutan Med"},{"key":"1517_CR24","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1111\/jdv.19665","volume":"38","author":"M Senna","year":"2024","unstructured":"Senna M, Mostaghimi A, Ohyama M, Sinclair R, Dutronc Y, Wu WS, et al. Long-term efficacy and safety of baricitinib in patients with severe alopecia areata: results from BRAVE-AA1 and BRAVE-AA2. J Eur Acad Dermatol Venereol. 2024;38:583\u201393.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1517_CR25","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1001\/jamadermatol.2024.2734","volume":"160","author":"B King","year":"2024","unstructured":"King B, Ko J, Kwon O, Va\u00f1\u00f3-Galv\u00e1n S, Piraccini BM, Dutronc Y, et al. Baricitinib withdrawal and retreatment in patients with severe alopecia areata: the BRAVE-AA1 randomized clinical trial. JAMA Dermatol. 2024;160:1075.","journal-title":"JAMA Dermatol"},{"key":"1517_CR26","unstructured":"Litfulo\u00ae (ritlecitinib) full prescribing information [Internet]. Pfizer Inc; Available from: https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=19638"},{"key":"1517_CR27","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/S0140-6736(23)00222-2","volume":"401","author":"B King","year":"2023","unstructured":"King B, Zhang X, Harcha WG, Szepietowski JC, Shapiro J, Lynde C, et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b\u20133 trial. Lancet. 2023;401:1518\u201329.","journal-title":"Lancet"},{"key":"1517_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.09.064","author":"M Piliang","year":"2024","unstructured":"Piliang M, Lynde C, King B, Mirmirani P, Sinclair R, Senna M, et al. Sustained hair regrowth with continued ritlecitinib treatment through week 48 in patients with alopecia areata with or without early target responses: post hoc analysis of the ALLEGRO phase 2b\/3 trial. J Am Acad Dermatol. 2024. https:\/\/doi.org\/10.1016\/j.jaad.2024.09.064.","journal-title":"J Am Acad Dermatol"},{"key":"1517_CR29","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae365","author":"M Piliang","year":"2024","unstructured":"Piliang M, Soung J, King B, Shapiro J, Rudnicka L, Farrant P, et al. Efficacy and safety of the oral Janus kinase 3\/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb\/III and long-term phase III clinical studies in alopecia areata. Br J Dermatol. 2024. https:\/\/doi.org\/10.1093\/bjd\/ljae365.","journal-title":"Br J Dermatol"},{"key":"1517_CR30","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.jaad.2021.12.008","volume":"87","author":"E Peeva","year":"2022","unstructured":"Peeva E, Guttman-Yassky E, Banerjee A, Sinclair R, Cox LA, Zhu L, et al. Maintenance, withdrawal, and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single-blind extension of a phase 2a randomized clinical trial. J Am Acad Dermatol. 2022;87:390\u20133.","journal-title":"J Am Acad Dermatol"},{"key":"1517_CR31","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1111\/1346-8138.17442","volume":"51","author":"N Mesinkovska","year":"2024","unstructured":"Mesinkovska N, King B, Zhang X, Guttman-Yassky E, Magnolo N, Sinclair R, et al. Efficacy and safety of ritlecitinib, an oral JAK3 \/ TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalis. J Dermatol. 2024;51:1414\u201324.","journal-title":"J Dermatol"},{"key":"1517_CR32","unstructured":"LEQSELVI\u00ae (deuruxolitinib) prescribing information [Internet]. U.S. Food and Drug Administration; Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/217900s000lbl.pdf"},{"key":"1517_CR33","unstructured":"Mirmirani P. Pooled data from the Phase 3 THRIVE-AA1 and THRIVE-AA2 trials. Amsterdam, Netherlands (2024)."},{"key":"1517_CR34","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.jaad.2024.06.097","volume":"91","author":"B King","year":"2024","unstructured":"King B, Senna MM, Mesinkovska NA, Lynde C, Zirwas M, Maari C, et al. Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: results from the phase 3 randomized, controlled trial (THRIVE-AA1). J Am Acad Dermatol. 2024;91:880\u20138.","journal-title":"J Am Acad Dermatol"},{"key":"1517_CR35","unstructured":"Deshpande A. Deuruxolitinib (CTP-543) Clinical Program Update [Internet]. (2023). Available from: https:\/\/archives.nseindia.com\/corporate\/SUNPHARMA_02052023084230_IntimationSigned.pdf"},{"key":"1517_CR36","unstructured":"King B. S050 late-breaking research: session 2. San Diego, CA (2024)."},{"key":"1517_CR37","doi-asserted-by":"publisher","first-page":"E203","DOI":"10.1016\/j.jaad.2024.11.086","volume":"92","author":"AJ Coppinger","year":"2025","unstructured":"Coppinger AJ, Wambier CG. Most men choose eyebrows versus scalp hair: response to Mostaghimi et al., \u201cEvaluation of eyebrow and eyelash regrowth and patient satisfaction in the phase 3 THRIVE-AA2 trial of deuruxolitinib in adult patients with alopecia areata.\u201d J Am Acad Dermatol. 2025;92:E203-4.","journal-title":"J Am Acad Dermatol"},{"key":"1517_CR38","unstructured":"Intimation under Regulation 30 of SEBI (Listing obligations and disclosure requirements) regulations, 2015 \u2013 order vacating preliminary injunction on LEQSELVITM [Internet]. Sun Pharma; (2025). Available from: https:\/\/www.bseindia.com\/xml-data\/corpfiling\/AttachLive\/58a225c1-aaf7-468f-a017-8ec5c0d81db8.pdf"},{"key":"1517_CR39","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1111\/ijd.15657","volume":"60","author":"VWY Lai","year":"2021","unstructured":"Lai VWY, Bokhari L, Sinclair R. Sublingual tofacitinib for alopecia areata: a roll-over pilot clinical trial and analysis of pharmacokinetics. Int J Dermatol. 2021;60:1135\u20139.","journal-title":"Int J Dermatol"},{"key":"1517_CR40","unstructured":"National Alopecia Areata Foundation. Approved treatments for alopecia areata. Available from: https:\/\/www.naaf.org\/approved-treatment-drug-page\/"},{"key":"1517_CR41","unstructured":"Pfizer. U.S. FDA Approves Pfizer\u2019s XELJANZ\u00ae (tofacitinib) for the treatment of active ankylosing spondylitis. (2021) Available from: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/us-fda-approves-pfizers-xeljanzr-tofacitinib-treatment-0"},{"key":"1517_CR42","unstructured":"U.S. Food and Drug Administration. FDA approves ruxolitinib for acute graft-versus-host disease. (2019) Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-ruxolitinib-acute-graft-versus-host-disease"},{"key":"1517_CR43","first-page":"75","volume":"8","author":"LA Raedler","year":"2015","unstructured":"Raedler LA. Jakafi (Ruxolitinib): first FDA-approved medication for the treatment of patients with polycythemia vera. Am Health Drug Benefits. 2015;8:75\u20139.","journal-title":"Am Health Drug Benefits"},{"key":"1517_CR44","doi-asserted-by":"publisher","first-page":"955035","DOI":"10.3389\/fimmu.2022.955035","volume":"13","author":"M Lensing","year":"2022","unstructured":"Lensing M, Jabbari A. An overview of JAK\/STAT pathways and JAK inhibition in alopecia areata. Front Immunol. 2022;13:955035.","journal-title":"Front Immunol"},{"key":"1517_CR45","unstructured":"Pfizer. Xeljanz Prescribing Information [Internet]. (2024). Available from: https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?format=PDF&id=959"},{"key":"1517_CR46","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1310\/hpj4805-413","volume":"48","author":"DJ Cada","year":"2013","unstructured":"Cada DJ, Demaris K, Levien TL, Baker DE. Tofacitinib. Hosp Pharm. 2013;48:413\u201324.","journal-title":"Hosp Pharm"},{"key":"1517_CR47","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1159\/000510673","volume":"7","author":"M Esteves","year":"2021","unstructured":"Esteves M, Lopes S, Azevedo F, Pedrosa A. Effectiveness of oral tofacitinib dose tapering in a case of alopecia areata universalis. Skin Appendage Disord. 2021;7:36\u201340.","journal-title":"Skin Appendage Disord"},{"key":"1517_CR48","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1684\/ejd.2019.3668","volume":"29","author":"Y-Y Chen","year":"2019","unstructured":"Chen Y-Y, Lin S-Y, Chen Y-C, Yang C-C, Lan C-CE. Low-dose tofacitinib for treating patients with severe alopecia areata: an efficient and cost-saving regimen. Eur J Dermatol EJD. 2019;29:667\u20139.","journal-title":"Eur J Dermatol EJD"},{"key":"1517_CR49","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1007\/s00403-024-03203-w","volume":"316","author":"M Paracha","year":"2024","unstructured":"Paracha M, Wasim M, Noor SM, Khan AQ, Sagheer F, Ahmad I. Comparison of efficacy and safety of tofacitinib and azathioprine in patients with alopecia areata and variants: a double-blind, randomized controlled trial. Arch Dermatol Res. 2024;316:458.","journal-title":"Arch Dermatol Res"},{"key":"1517_CR50","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jaad.2016.09.007","volume":"76","author":"LY Liu","year":"2017","unstructured":"Liu LY, Craiglow BG, Dai F, King BA. Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients. J Am Acad Dermatol. 2017;76:22\u20138.","journal-title":"J Am Acad Dermatol"},{"key":"1517_CR51","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1159\/000494613","volume":"235","author":"N Almutairi","year":"2019","unstructured":"Almutairi N, Nour TM, Hussain NH. Janus kinase inhibitors for the treatment of severe alopecia areata: an open-label comparative study. Dermatology. 2019;235:130\u20136.","journal-title":"Dermatology"},{"key":"1517_CR52","doi-asserted-by":"crossref","unstructured":"Kennedy Crispin M, Ko JM, Craiglow BG, Li S, Shankar G, Urban JR, et al. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. JCI Insight [Internet]. (2016) [cited 2024 Dec 15];1. Available from: https:\/\/insight.jci.org\/articles\/view\/89776","DOI":"10.1172\/jci.insight.89776"},{"key":"1517_CR53","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v103.12425","volume":"103","author":"J Huang","year":"2023","unstructured":"Huang J, Qian P, Tang Y, Li J, Liu F, Shi W. Effectiveness and predictive factors of response to tofacitinib therapy in 125 patients with alopecia areata: a single-centre real-world retrospective study. Acta Derm Venereol. 2023;103: adv12425.","journal-title":"Acta Derm Venereol"},{"key":"1517_CR54","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386:316\u201326.","journal-title":"N Engl J Med"},{"key":"1517_CR55","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1016\/j.jid.2018.01.032","volume":"138","author":"A Jabbari","year":"2018","unstructured":"Jabbari A, Sansaricq F, Cerise J, Chen JC, Bitterman A, Ulerio G, et al. An open-label pilot study to evaluate the efficacy of tofacitinib in moderate to severe patch-type alopecia areata, totalis, and universalis. J Invest Dermatol. 2018;138:1539\u201345.","journal-title":"J Invest Dermatol"},{"key":"1517_CR56","doi-asserted-by":"publisher","DOI":"10.1111\/pde.15882","author":"R Mahajan","year":"2025","unstructured":"Mahajan R, Mehta H, De D, Handa S. Oral tofacitinib for the management of moderate to severe alopecia areata in children and adolescents: a retrospective study of 36 patients. Pediatr Dermatol. 2025. https:\/\/doi.org\/10.1111\/pde.15882.","journal-title":"Pediatr Dermatol"},{"key":"1517_CR57","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s40262-023-01225-7","volume":"62","author":"TYJ Appeldoorn","year":"2023","unstructured":"Appeldoorn TYJ, Munnink THO, Morsink LM, Hooge MNL, Touw DJ. Pharmacokinetics and pharmacodynamics of ruxolitinib: a review. Clin Pharmacokinet. 2023;62:559\u201371.","journal-title":"Clin Pharmacokinet"},{"key":"1517_CR58","unstructured":"Incyte Corporation. Jakafi Prescribing Information. (2023)."},{"key":"1517_CR59","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.jdcr.2020.02.007","volume":"6","author":"DM Peterson","year":"2020","unstructured":"Peterson DM, Vesely MD. Successful treatment of alopecia totalis with ruxolitinib in a preadolescent patient. JAAD Case Rep. 2020;6:257\u20139.","journal-title":"JAAD Case Rep"},{"key":"1517_CR60","doi-asserted-by":"publisher","first-page":"384","DOI":"10.3390\/jpm13030384","volume":"13","author":"M Tampa","year":"2023","unstructured":"Tampa M, Mitran CI, Mitran MI, Georgescu SR. A new horizon for atopic dermatitis treatments: JAK inhibitors. J Pers Med. 2023;13:384.","journal-title":"J Pers Med"},{"key":"1517_CR61","first-page":"43","volume":"16","author":"R Wlassits","year":"2024","unstructured":"Wlassits R, M\u00fcller M, Fenzl KH, Lamprecht T, Erlacher L. JAK-inhibitors - a story of success and adverse events. Open Access Rheumatol Res Rev. 2024;16:43\u201353.","journal-title":"Open Access Rheumatol Res Rev"},{"key":"1517_CR62","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.jaci.2015.12.1318","volume":"137","author":"J Krueger","year":"2016","unstructured":"Krueger J, Clark JD, Su\u00e1rez-Fari\u00f1as M, Fuentes-Duculan J, Cueto I, Wang CQ, et al. Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: a randomized phase 2 study. J Allergy Clin Immunol. 2016;137:1079\u201390.","journal-title":"J Allergy Clin Immunol"},{"key":"1517_CR63","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1111\/bjd.14871","volume":"175","author":"R Bissonnette","year":"2016","unstructured":"Bissonnette R, Papp KA, Poulin Y, Gooderham M, Raman M, Mallbris L, et al. Topical tofacitinib for atopic dermatitis: a phase II a randomized trial. Br J Dermatol. 2016;175:902\u201311.","journal-title":"Br J Dermatol"},{"key":"1517_CR64","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1111\/ijd.14192","volume":"57","author":"L Bokhari","year":"2018","unstructured":"Bokhari L, Sinclair R. Treatment of alopecia universalis with topical Janus kinase inhibitors \u2013 a double blind, placebo, and active controlled pilot study. Int J Dermatol. 2018;57:1464\u201370.","journal-title":"Int J Dermatol"},{"key":"1517_CR65","unstructured":"Opzelura (ruxolitinib) cream, 1.5% prescribing guide [Internet]. Incyte Corporation; (2024) [cited 2024 Dec 16]. Available from: https:\/\/www.incytepicentral.com\/sites\/g\/files\/hssmmz4016\/files\/2024-08\/opzelura-prescribing-information.pdf#page=1"},{"key":"1517_CR66","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.jaad.2019.10.016","volume":"82","author":"EA Olsen","year":"2020","unstructured":"Olsen EA, Kornacki D, Sun K, Hordinsky MK. Ruxolitinib cream for the treatment of patients with alopecia areata: a 2-part, double-blind, randomized, vehicle-controlled phase 2 study. J Am Acad Dermatol. 2020;82:412\u20139.","journal-title":"J Am Acad Dermatol"},{"key":"1517_CR67","doi-asserted-by":"publisher","first-page":"1152513","DOI":"10.3389\/fimmu.2023.1152513","volume":"14","author":"D Wei","year":"2023","unstructured":"Wei D, Chen Y, Shen Y, Xie B, Song X. Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: a network meta-analysis. Front Immunol. 2023;14:1152513.","journal-title":"Front Immunol"},{"key":"1517_CR68","doi-asserted-by":"publisher","first-page":"107830","DOI":"10.1016\/j.pharmthera.2021.107830","volume":"224","author":"X Yang","year":"2021","unstructured":"Yang X, Kambe N, Takimoto-Ito R, Kabashima K. Advances in the pathophysiology of atopic dermatitis revealed by novel therapeutics and clinical trials. Pharmacol Ther. 2021;224:107830.","journal-title":"Pharmacol Ther"},{"key":"1517_CR69","unstructured":"ANZUPGO (delgocitinib) product information [Internet]. European Medicines Agency; (2024) [cited 2024 Dec 16]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/anzupgo-epar-product-information_en.pdf"},{"key":"1517_CR70","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s00403-022-02336-0","volume":"315","author":"D Mikhaylov","year":"2022","unstructured":"Mikhaylov D, Glickman JW, Del Duca E, Nia J, Hashim P, Singer GK, et al. A phase 2a randomized vehicle-controlled multi-center study of the safety and efficacy of delgocitinib in subjects with moderate-to-severe alopecia areata. Arch Dermatol Res. 2022;315:181\u20139.","journal-title":"Arch Dermatol Res"},{"key":"1517_CR71","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/j.jaad.2023.05.001","volume":"89","author":"A Chiricozzi","year":"2023","unstructured":"Chiricozzi A, Balato A, Fabbrocini G, Di Nardo L, Babino G, Rossi M, et al. Beneficial effects of upadacitinib on alopecia areata associated with atopic dermatitis: a multicenter retrospective study. J Am Acad Dermatol. 2023;89:1251\u20133.","journal-title":"J Am Acad Dermatol"},{"key":"1517_CR72","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jaad.2022.12.056","volume":"89","author":"A Flora","year":"2023","unstructured":"Flora A, Kozera E, Frew JW. Treatment of alopecia areata with the janus kinase inhibitor upadacitinib: a retrospective cohort study. J Am Acad Dermatol. 2023;89:137\u20138.","journal-title":"J Am Acad Dermatol"},{"key":"1517_CR73","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.jaad.2023.02.063","volume":"89","author":"C Zhou","year":"2023","unstructured":"Zhou C, Yang X, Yang B, Yan G, Dong X, Ding Y, et al. A randomized, double-blind, placebo-controlled phase II study to evaluate the efficacy and safety of ivarmacitinib (SHR0302) in adult patients with moderate-to-severe alopecia areata. J Am Acad Dermatol. 2023;89:911\u20139.","journal-title":"J Am Acad Dermatol"},{"key":"1517_CR74","unstructured":"Study to Evaluate the Safety and Efficacy ofJaktinib Hydrochloride Tablets in Severe Alopecia Areata [Internet]. Suzhou Zelgen Biopharmaceuticals Co.,Ltd; [cited 2025 Jan 24]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04034134?a=8"},{"key":"1517_CR75","doi-asserted-by":"publisher","first-page":"2050313X2312131","DOI":"10.1177\/2050313X231213135","volume":"11","author":"S Oliel","year":"2023","unstructured":"Oliel S, Moussa S, Stanciu M, Netchiporouk E. Rapid hair regrowth in an alopecia universalis patient with deucravacitinib: a case report. SAGE Open Med Case Rep. 2023;11:2050313X231213135.","journal-title":"SAGE Open Med Case Rep"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01517-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01517-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01517-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T13:25:39Z","timestamp":1758720339000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01517-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":75,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1517"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01517-9","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]},"assertion":[{"value":"29 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Arash Mostaghimi has received consulting fees from AbbVie, ACOM Health, Bioniz, Boehringer Ingelheim, Concert, Digital Diagnostics, Eli Lilly, Equillium, Hims & Hers Health, and Pfizer; equity from ACOM Health, Figure-1, and Hims & Hers Health; licensing\/royalties from Concert and Pfizer; and research funding from Aclaris, Concert, Eli Lilly, and Incyte. Dr. Arash Mostaghimi is a member of the Editorial Board for Dermatology and Therapy. Dr. Arash Mostaghimi was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Katherine Sanchez, Hanna Englander, Lana Salloum, Samantha Gregoire, Ursula Biba, and Sherry Ershadi have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}